2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,906VWAP
Alin
4,65VaihtoMäärä
5,8 1 222 387
VWAP
Ylin
4,906Alin
4,65VaihtoMäärä
5,8 1 222 387
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 20.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenFebruary 25, 2026 / 17:11 CET/CEST First Berlin Equity Research has reviewed Valneva's new figures for 2025 and forecasts for 2026, and analyst Simon Scholes confirms his BUY recommendation, but lowers the price target from 6.80 euros to 6.60 euros. Summary Valneva has published preliminary figures for sales and cash flow for 2025, and provided an initial forecast for 2026. Product Sales 2025: 157.9 million euros – (First Berlin estimate: 155.1 million euros; 2024: 163.3 million euros) – Was in the lower part of the company's forecast (155–170 million euros) – 1.8 % above First Berlin's estimate – 2.8 % below last year, mainly due to a sharp drop in third-party sales Third-party sales: fell 43.2 % to 19.2 million euros (2024: 33.2 million euros) Adjusted for currency and excluding third-party sales: product sales increased by 9.0 % Reason for the drop in third-party sales: The distribution agreement with Bavarian Nordic expires at the end of 2025. Cash balance at the end of 2025: 109.7 million euros – Significantly above First Berlin's forecast of 86 million euros – Indicates that Valneva is financially stronger before the transition to positive free cash flow in connection with the launch of the Lyme vaccine Forecast for 2026: Product Sales 145–160 million euros – The midpoint is 3.4 % below 2025 – 10.9 % below First Berlin's previous forecast – The decline is due to the continued discontinuation of third-party sales Lyme vaccine (VLA15): – Phase 3 data is expected before the end of June 2026 – Upon approval, the vaccine will be launched in autumn 2027 – First Berlin's assumptions about VLA15 remain unchanged Conclusion First Berlin maintains BUY, but lowers the price target to 6.60 euros to reflect lower expectations for revenues and earnings from established products in 2026 and subsequent years. The valuation of VLA15 is unchanged. https://live.deutsche-boerse.com/nachrichten/Original-Research-Valneva-von-First-Berlin-Equity-Research-GmbH-Buy-c29b3f6a-aabc-45a0-a3dc-edfd775fb5d9- ·19.2.Briefly summarized: Valneva preliminary 2025 figures and 2026 outlook Results for 2025 (preliminary, unaudited) Total revenues: €174.7 million Product sales: €157.9 million In line with previous guidance Cash balance at year-end: €109.7 million Increased financial flexibility after successful debt refinancing Outlook for 2026 The company describes 2026 as a potentially transformative year Phase 3 data for the Lyme vaccine expected in the first half of 2026 – This is Valneva's most important development program and a possible game-changer for the company Management CEO contract renewed for an additional three years – Provides stability and continuity in management The full report can be found here: https://valneva.com/wp-content/uploads/2026/02/2026_02_19_FY2025_RevCash_PR_EN_Final.pdf
- ·14.2.Valneva provides update on recommendations for use of IXCHIQ® in the United Kingdom Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today that following a review of the benefits and risks of the company's single-dose chikungunya vaccine, IXCHIQ®, the UK's Commission on Human Medicines (CHM) has updated its recommendations for the use of the vaccine. The updated Product Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for individuals with specified health conditions, as well as the timing of vaccination before travel. For further details, please see the link. MHRA confirmed that the benefit-risk profile for IXCHIQ® remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection and who do not have the contra-indicated underlying medical conditions. The update follows MHRA's temporary suspension of the use of IXCHIQ® in elderly individuals¹, which was based on reports of serious adverse events (SAEs), mainly in elderly people with significant underlying medical conditions during a vaccination campaign during an outbreak on the French island of La Réunion. Valneva is committed to maintaining the highest safety standards and will continue to monitor post-marketing safety data for IXCHIQ® and work collaboratively with all relevant authorities to potentially update recommendations and usage restrictions if warranted. About chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread through the bite of infected Aedes mosquitoes, causing fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. Joint pain is often debilitating and can persist for weeks to years². In 2004, the disease began to spread rapidly, causing large outbreaks worldwide. Since the re-emergence of the virus, CHIKV has been identified in over 110 countries in Asia, Africa, Europe, and the Americas³. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas³, and the economic impact is considered significant. The medical and economic burden is expected to increase with climate change as the mosquito species that spread the disease continue to spread geographically. The World Health Organization (WHO) has therefore highlighted chikungunya as a major public health problem⁴. About Valneva SE We are a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine technologies, with a focus on delivering either first-, best-, or only-in-class vaccine solutions. We have a strong track record, having developed several vaccines from early research to approval, and currently market three proprietary travel vaccines. Revenues from our growing commercial operations contribute to funding further development of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is in partnership with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against Zika virus and other global public health threats. More information can be found at www.valneva.com.. https://www.nordnet.no/market/news/c0420bf3-17f7-4f77-8754-a76050abe9fe
- ·4.2.Short summary of the press release from Valneva (February 3, 2026) Valneva and Instituto Butantan have launched a pilot vaccination program in Brazil to use Valneva's single-dose chikungunya vaccine, IXCHIQ®, in real-world populations. This will provide post-marketing data on how well the vaccine works and how safe it is when used on a large scale. Key points The program is being implemented in 10 selected Brazilian municipalities. The target group is adults aged 18–59, and the goal is 20–40 % vaccination coverage. Valneva is donating up to 500,000 doses via Instituto Butantan. IXCHIQ® received approval in Brazil in April 2025, as the first chikungunya vaccine approved in a country where the disease is endemic. Brazil has had over one million chikungunya cases since 2019, and WHO warns of the risk of larger global outbreaks. Statements from management Valneva's Chief Medical Officer says the program will provide important real-world evidence and strengthen understanding of the vaccine in areas with active transmission. The Director of Instituto Butantan emphasizes that the program builds on close scientific and regulatory collaboration. Background Chikungunya is spread via Aedes mosquitoes and can cause long-lasting joint pain. Climate change is expected to increase the disease's geographical spread. Valneva and Instituto Butantan have collaborated since 2021 on technology transfer and production for Latin America. The project is supported by CEPI and the EU program Horizon Europe. https://www.nordnet.no/market/news/1577445d-1b3e-4551-be48-649f4de60731
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenFebruary 25, 2026 / 17:11 CET/CEST First Berlin Equity Research has reviewed Valneva's new figures for 2025 and forecasts for 2026, and analyst Simon Scholes confirms his BUY recommendation, but lowers the price target from 6.80 euros to 6.60 euros. Summary Valneva has published preliminary figures for sales and cash flow for 2025, and provided an initial forecast for 2026. Product Sales 2025: 157.9 million euros – (First Berlin estimate: 155.1 million euros; 2024: 163.3 million euros) – Was in the lower part of the company's forecast (155–170 million euros) – 1.8 % above First Berlin's estimate – 2.8 % below last year, mainly due to a sharp drop in third-party sales Third-party sales: fell 43.2 % to 19.2 million euros (2024: 33.2 million euros) Adjusted for currency and excluding third-party sales: product sales increased by 9.0 % Reason for the drop in third-party sales: The distribution agreement with Bavarian Nordic expires at the end of 2025. Cash balance at the end of 2025: 109.7 million euros – Significantly above First Berlin's forecast of 86 million euros – Indicates that Valneva is financially stronger before the transition to positive free cash flow in connection with the launch of the Lyme vaccine Forecast for 2026: Product Sales 145–160 million euros – The midpoint is 3.4 % below 2025 – 10.9 % below First Berlin's previous forecast – The decline is due to the continued discontinuation of third-party sales Lyme vaccine (VLA15): – Phase 3 data is expected before the end of June 2026 – Upon approval, the vaccine will be launched in autumn 2027 – First Berlin's assumptions about VLA15 remain unchanged Conclusion First Berlin maintains BUY, but lowers the price target to 6.60 euros to reflect lower expectations for revenues and earnings from established products in 2026 and subsequent years. The valuation of VLA15 is unchanged. https://live.deutsche-boerse.com/nachrichten/Original-Research-Valneva-von-First-Berlin-Equity-Research-GmbH-Buy-c29b3f6a-aabc-45a0-a3dc-edfd775fb5d9
- ·19.2.Briefly summarized: Valneva preliminary 2025 figures and 2026 outlook Results for 2025 (preliminary, unaudited) Total revenues: €174.7 million Product sales: €157.9 million In line with previous guidance Cash balance at year-end: €109.7 million Increased financial flexibility after successful debt refinancing Outlook for 2026 The company describes 2026 as a potentially transformative year Phase 3 data for the Lyme vaccine expected in the first half of 2026 – This is Valneva's most important development program and a possible game-changer for the company Management CEO contract renewed for an additional three years – Provides stability and continuity in management The full report can be found here: https://valneva.com/wp-content/uploads/2026/02/2026_02_19_FY2025_RevCash_PR_EN_Final.pdf
- ·14.2.Valneva provides update on recommendations for use of IXCHIQ® in the United Kingdom Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today that following a review of the benefits and risks of the company's single-dose chikungunya vaccine, IXCHIQ®, the UK's Commission on Human Medicines (CHM) has updated its recommendations for the use of the vaccine. The updated Product Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for individuals with specified health conditions, as well as the timing of vaccination before travel. For further details, please see the link. MHRA confirmed that the benefit-risk profile for IXCHIQ® remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection and who do not have the contra-indicated underlying medical conditions. The update follows MHRA's temporary suspension of the use of IXCHIQ® in elderly individuals¹, which was based on reports of serious adverse events (SAEs), mainly in elderly people with significant underlying medical conditions during a vaccination campaign during an outbreak on the French island of La Réunion. Valneva is committed to maintaining the highest safety standards and will continue to monitor post-marketing safety data for IXCHIQ® and work collaboratively with all relevant authorities to potentially update recommendations and usage restrictions if warranted. About chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread through the bite of infected Aedes mosquitoes, causing fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. Joint pain is often debilitating and can persist for weeks to years². In 2004, the disease began to spread rapidly, causing large outbreaks worldwide. Since the re-emergence of the virus, CHIKV has been identified in over 110 countries in Asia, Africa, Europe, and the Americas³. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas³, and the economic impact is considered significant. The medical and economic burden is expected to increase with climate change as the mosquito species that spread the disease continue to spread geographically. The World Health Organization (WHO) has therefore highlighted chikungunya as a major public health problem⁴. About Valneva SE We are a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine technologies, with a focus on delivering either first-, best-, or only-in-class vaccine solutions. We have a strong track record, having developed several vaccines from early research to approval, and currently market three proprietary travel vaccines. Revenues from our growing commercial operations contribute to funding further development of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is in partnership with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against Zika virus and other global public health threats. More information can be found at www.valneva.com.. https://www.nordnet.no/market/news/c0420bf3-17f7-4f77-8754-a76050abe9fe
- ·4.2.Short summary of the press release from Valneva (February 3, 2026) Valneva and Instituto Butantan have launched a pilot vaccination program in Brazil to use Valneva's single-dose chikungunya vaccine, IXCHIQ®, in real-world populations. This will provide post-marketing data on how well the vaccine works and how safe it is when used on a large scale. Key points The program is being implemented in 10 selected Brazilian municipalities. The target group is adults aged 18–59, and the goal is 20–40 % vaccination coverage. Valneva is donating up to 500,000 doses via Instituto Butantan. IXCHIQ® received approval in Brazil in April 2025, as the first chikungunya vaccine approved in a country where the disease is endemic. Brazil has had over one million chikungunya cases since 2019, and WHO warns of the risk of larger global outbreaks. Statements from management Valneva's Chief Medical Officer says the program will provide important real-world evidence and strengthen understanding of the vaccine in areas with active transmission. The Director of Instituto Butantan emphasizes that the program builds on close scientific and regulatory collaboration. Background Chikungunya is spread via Aedes mosquitoes and can cause long-lasting joint pain. Climate change is expected to increase the disease's geographical spread. Valneva and Instituto Butantan have collaborated since 2021 on technology transfer and production for Latin America. The project is supported by CEPI and the EU program Horizon Europe. https://www.nordnet.no/market/news/1577445d-1b3e-4551-be48-649f4de60731
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,906VWAP
Alin
4,65VaihtoMäärä
5,8 1 222 387
VWAP
Ylin
4,906Alin
4,65VaihtoMäärä
5,8 1 222 387
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 20.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 20.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenFebruary 25, 2026 / 17:11 CET/CEST First Berlin Equity Research has reviewed Valneva's new figures for 2025 and forecasts for 2026, and analyst Simon Scholes confirms his BUY recommendation, but lowers the price target from 6.80 euros to 6.60 euros. Summary Valneva has published preliminary figures for sales and cash flow for 2025, and provided an initial forecast for 2026. Product Sales 2025: 157.9 million euros – (First Berlin estimate: 155.1 million euros; 2024: 163.3 million euros) – Was in the lower part of the company's forecast (155–170 million euros) – 1.8 % above First Berlin's estimate – 2.8 % below last year, mainly due to a sharp drop in third-party sales Third-party sales: fell 43.2 % to 19.2 million euros (2024: 33.2 million euros) Adjusted for currency and excluding third-party sales: product sales increased by 9.0 % Reason for the drop in third-party sales: The distribution agreement with Bavarian Nordic expires at the end of 2025. Cash balance at the end of 2025: 109.7 million euros – Significantly above First Berlin's forecast of 86 million euros – Indicates that Valneva is financially stronger before the transition to positive free cash flow in connection with the launch of the Lyme vaccine Forecast for 2026: Product Sales 145–160 million euros – The midpoint is 3.4 % below 2025 – 10.9 % below First Berlin's previous forecast – The decline is due to the continued discontinuation of third-party sales Lyme vaccine (VLA15): – Phase 3 data is expected before the end of June 2026 – Upon approval, the vaccine will be launched in autumn 2027 – First Berlin's assumptions about VLA15 remain unchanged Conclusion First Berlin maintains BUY, but lowers the price target to 6.60 euros to reflect lower expectations for revenues and earnings from established products in 2026 and subsequent years. The valuation of VLA15 is unchanged. https://live.deutsche-boerse.com/nachrichten/Original-Research-Valneva-von-First-Berlin-Equity-Research-GmbH-Buy-c29b3f6a-aabc-45a0-a3dc-edfd775fb5d9
- ·19.2.Briefly summarized: Valneva preliminary 2025 figures and 2026 outlook Results for 2025 (preliminary, unaudited) Total revenues: €174.7 million Product sales: €157.9 million In line with previous guidance Cash balance at year-end: €109.7 million Increased financial flexibility after successful debt refinancing Outlook for 2026 The company describes 2026 as a potentially transformative year Phase 3 data for the Lyme vaccine expected in the first half of 2026 – This is Valneva's most important development program and a possible game-changer for the company Management CEO contract renewed for an additional three years – Provides stability and continuity in management The full report can be found here: https://valneva.com/wp-content/uploads/2026/02/2026_02_19_FY2025_RevCash_PR_EN_Final.pdf
- ·14.2.Valneva provides update on recommendations for use of IXCHIQ® in the United Kingdom Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today that following a review of the benefits and risks of the company's single-dose chikungunya vaccine, IXCHIQ®, the UK's Commission on Human Medicines (CHM) has updated its recommendations for the use of the vaccine. The updated Product Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for individuals with specified health conditions, as well as the timing of vaccination before travel. For further details, please see the link. MHRA confirmed that the benefit-risk profile for IXCHIQ® remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection and who do not have the contra-indicated underlying medical conditions. The update follows MHRA's temporary suspension of the use of IXCHIQ® in elderly individuals¹, which was based on reports of serious adverse events (SAEs), mainly in elderly people with significant underlying medical conditions during a vaccination campaign during an outbreak on the French island of La Réunion. Valneva is committed to maintaining the highest safety standards and will continue to monitor post-marketing safety data for IXCHIQ® and work collaboratively with all relevant authorities to potentially update recommendations and usage restrictions if warranted. About chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread through the bite of infected Aedes mosquitoes, causing fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. Joint pain is often debilitating and can persist for weeks to years². In 2004, the disease began to spread rapidly, causing large outbreaks worldwide. Since the re-emergence of the virus, CHIKV has been identified in over 110 countries in Asia, Africa, Europe, and the Americas³. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas³, and the economic impact is considered significant. The medical and economic burden is expected to increase with climate change as the mosquito species that spread the disease continue to spread geographically. The World Health Organization (WHO) has therefore highlighted chikungunya as a major public health problem⁴. About Valneva SE We are a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine technologies, with a focus on delivering either first-, best-, or only-in-class vaccine solutions. We have a strong track record, having developed several vaccines from early research to approval, and currently market three proprietary travel vaccines. Revenues from our growing commercial operations contribute to funding further development of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is in partnership with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against Zika virus and other global public health threats. More information can be found at www.valneva.com.. https://www.nordnet.no/market/news/c0420bf3-17f7-4f77-8754-a76050abe9fe
- ·4.2.Short summary of the press release from Valneva (February 3, 2026) Valneva and Instituto Butantan have launched a pilot vaccination program in Brazil to use Valneva's single-dose chikungunya vaccine, IXCHIQ®, in real-world populations. This will provide post-marketing data on how well the vaccine works and how safe it is when used on a large scale. Key points The program is being implemented in 10 selected Brazilian municipalities. The target group is adults aged 18–59, and the goal is 20–40 % vaccination coverage. Valneva is donating up to 500,000 doses via Instituto Butantan. IXCHIQ® received approval in Brazil in April 2025, as the first chikungunya vaccine approved in a country where the disease is endemic. Brazil has had over one million chikungunya cases since 2019, and WHO warns of the risk of larger global outbreaks. Statements from management Valneva's Chief Medical Officer says the program will provide important real-world evidence and strengthen understanding of the vaccine in areas with active transmission. The Director of Instituto Butantan emphasizes that the program builds on close scientific and regulatory collaboration. Background Chikungunya is spread via Aedes mosquitoes and can cause long-lasting joint pain. Climate change is expected to increase the disease's geographical spread. Valneva and Instituto Butantan have collaborated since 2021 on technology transfer and production for Latin America. The project is supported by CEPI and the EU program Horizon Europe. https://www.nordnet.no/market/news/1577445d-1b3e-4551-be48-649f4de60731
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,906VWAP
Alin
4,65VaihtoMäärä
5,8 1 222 387
VWAP
Ylin
4,906Alin
4,65VaihtoMäärä
5,8 1 222 387
Välittäjätilasto
Dataa ei löytynyt